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(pain and function) translated into an improvement of SF12 physical
component. Improvement was achieved as from W6 and maintained up to
W24. Changes of the VAS and LFI score between baseline and W24 were
respectively -29,0 (21,9) and -4,1 (3,1) in Structum group and -29,9 (22,3)
and -4,1 (3,2) in Chondrosulf group. OMERACT-OARSI responders rates at
week 24 were 76,3% in Structum and 73,8% in Chondrosulf group (PP).
Rescue medication use (paracetamol and/or NSAIDs) was low and similar
in the 2 groups. 37.4% and 33.1% in the Structum and in the Chondrosulf
group respectively did not take any rescue medication. Both treatments
were well tolerated with a discontinuation rate for safety of 2.4% in the
Structum group and 4.5% in Chondrosulf group.
Conclusions: Structum® 1000mg (500mg BID) and Chondrosulf® 1200mg
(400mg TID) were equally effective on pain relief and functional improve-
ment in patients with symptomatic knee OA over a 6 month period of
time. The improvement started as early as week 6 and persists over the 24
weeks. Eﬃcacy was also conﬁrmed by the high rate of responders, around
75% in each group.
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Purpose: Selective COX-2 inhibitors are frequently used in treatment of
osteoarthritis (OA) to control inﬂammation and relieve pain. In vitro and
ex vivo research using human articular cartilage, demonstrated an inﬂam-
mation independent chondroprotective effect of celecoxib. Such effects are
diﬃcult to verify in clinical trials because changes in OA cartilage, degen-
erative and reparative, are slow and evaluation by image and biomarker
techniques are still hampered by their limited sensitivity. Therefore, pa-
tients were treated in vivo several weeks prior to joint replacement surgery.
At the moment of surgery, cartilage was obtained and analyzed ex vivo
in detail. Three recent small studies using this approach demonstrated a
beneﬁcial effect of celecoxib at chondrocyte mRNA and protein level, and
at the level of matrix integrity suggesting disease modifying characteristics
of celecoxib.
These positive results tempted us to perform a well designed and powered
RCT to evaluate the disease modifying properties of celecoxib in treatment
of end-stage OA.
Methods: Patients (n=172) with end-stage knee OA on the waiting list for
knee replacement surgery were randomized to 4 groups and treated for at
least 4 weeks prior to surgery: celecoxib 2dd200mg, naproxen 2dd250mg
stopped 3 days prior to surgery (because of its platelet-inhibiting effect),
celecoxib 2dd200mg also stopped 3 days prior to surgery, or no treatment.
Cartilage and synovial tissue were collected during surgery and analyzed
in detail ex vivo fully blinded to the treatment until all data were ob-
tained. Primary outcome was cartilage proteoglycan release. Additionally,
several biochemical markers of cartilage integrity and synovial inﬂamma-
Abstract 329 – Table 1. Changes in Proprioception scores
Variable Mean Scores (SD) Change from BaselineMean (SD) Total Number of Subjects P-value Tai Chi vs. Control
Tai Chi (N=20) Control (N=20) Tai Chi Control
30 Degrees
Baseline 5.58 (4.15) 4.26 (2.88)
Week 12 3.00 (2.55) 6.55 (4.38) -2.53 (5.22) 2.11 (5.64) 40 0.01
Week 24 3.60 (4.58) 3.80 (2.50) -2.58 (5.84) -0.68 (2.60) 40 0.20
Week 48 4.10 (2.79) 4.79 (4.70) -1.26 (4.75) -0.11 (4.42) 39 0.40
45 Degrees
Baseline 4.60 (4.03) 3.63 (3.08)
Week 12 4.00 (3.29) 4.75 (4.12) -0.60 (5.06) 0.95 (5.04) 40 0.30
Week 24 2.75 (2.59) 1.65 (1.73) -1.85 (4.40) -1.95 (3.27) 40 0.90
Week 48 2.75 (1.55) 3.00 (2.98) -1.85 (4.52) -1.22 (4.41) 39 0.70
60 Degrees
Baseline 3.05 (3.05) 3.24 (2.93)
Week 12 2.45 (2.44) 2.84 (2.61) -0.60 (4.03) 0.06 (3.80) 39 0.60
Week 24 1.94 (2.46) 3.60 (3.31) -1.18 (3.28) -0.88 (3.76) 27 0.80
Week 48 3.21 (2.44) 1.94 (1.89) 0.26 (4.59) -1.44 (4.11) 37 0.30
tion were determined. The WOMAC questionnaire was used to evaluate
pain, stiffness and function before and after treatment. The study was
conducted according to the declaration of Helsinki and registered EudraCT
nr 2007-004862-41.
Results: 4 patients withdrew their consent, 10 changed medications within
2 weeks, and of 20 patients insuﬃcient tissue was obtained. Drop-outs
were equally distributed over the 4 treatment arms. Data were analyzed
by intention to treat as well as per protocol of the remaining 138 pa-
tients. At inclusion, age, gender, weight (BMI) and cartilage damage (X-ray,
macroscopic or histological) did not differ between the 4 randomized
groups. Unexpectedly, cartilage proteoglycan release was not different
between the 4 treatments. Also the other biochemical cartilage parameters
did not differ between the 4 groups. Furthermore, prostaglandin-E2 and
nitric oxide (NO) levels produced by the cartilage remained unchanged
compared to the no-treatment group. The ex vivo release of inﬂammatory
mediators IL-1β, TNFα, PGE2 and NO by the synovial tissue only showed a
statistical signiﬁcant decrease in NO levels in the celecoxib treated group
compared to the no-treatment group. Celecoxib treatment showed a slight
improvement in WOMAC pain (p<0.01), function and total score compared
to the no-treatment group.
Conclusions: No clear effect of celecoxib treatment on cartilage was evident
in the present study. Also the effects on synovial inﬂammatory mediators
were limited. Only a small beneﬁcial effect on WOMAC scores was found.
As such the reported in vivo disease modifying effects of celecoxib could
not be conﬁrmed in a suﬃciently powered single blinded RCT.
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Purpose: Neurologic deﬁcits, especially quadriceps sensory dysfunction
(i.e., decreased proprioceptive acuity) may precede Knee Osteoarthritis
(KOA) and are proposed to be a factor in its pathogenesis or progression.
Tai Chi may provide ideal proprioceptive exercise to older individuals
with KOA through its emphasis on balance, muscle strengthening, and
integration of the mind and body. Previous long-term observational stud-
ies found that Tai Chi practitioners had better knee-joint proprioceptive
acuity versus controls in an older population. We evaluated the effects of
Tai Chi for knee-joint proprioception in KOA in a randomized controlled
trial.
Methods: We randomized 40 eligible individuals (age > 55, BMI ≤ 40
kg/m2 with knee pain on most days of the previous month and tibiofemoral
OA K/L grade ≥2) to Tai Chi (10 modiﬁed forms from classical Yang style)
or an attention control (stretching and wellness education). The 60-minute
intervention sessions occurred twice-weekly for 12 weeks. The knee joint
proprioception was measured using a Biometrics™ electrogoniometer with
an ADU301 angle display unit during each assessment visit. Three test
angles (30, 45 and 60 degrees) were evaluated with each subject in a
sitting position taken as neutral (0 degree). The electrogoniometer was
placed longitudinally in alignment with the femur and tibia with double-
